Despite Seres Therapeutics Inc [MCRB]’s great opportunity, the stock is a bit overvalued

In yesterday’s Wall Street session, Seres Therapeutics Inc (NASDAQ:MCRB) shares traded at $0.74, up 20.54% from the previous session.

MCRB stock price is now -13.82% away from the 50-day moving average and -45.67% away from the 200-day moving average. The market capitalization of the company currently stands at $112.09M.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

Sponsored

On April 21, 2023, JP Morgan recently initiated its ‘Neutral’ rating on the stock quoting a target price of $7, while ‘Goldman’ rates the stock as ‘Sell’

In other news, Shaff Eric D., CEO and President sold 2,435 shares of the company’s stock on May 15 ’24. The stock was sold for $2,289 at an average price of $0.94. Upon completion of the transaction, the CEO and President now directly owns 140,698 shares in the company, valued at $0.1 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 15 ’24, Ege David S. sold 1,090 shares of the business’s stock. A total of $1,025 was realized by selling the stock at an average price of $0.94. This leaves the insider owning 75,734 shares of the company worth $56043.16. A total of 20.92% of the company’s stock is owned by insiders.

During the past 12 months, Seres Therapeutics Inc has had a low of $0.54 and a high of $6.26. The fifty day moving average price for MCRB is $0.8581 and a two-hundred day moving average price translates $1.348095 for the stock.

The latest earnings results from Seres Therapeutics Inc (NASDAQ: MCRB) was released for 2024-03-31. The net profit margin was -65.18% and return on equity was -538.57% for MCRB.

Related Posts